Aisha M. Mergaert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aisha M. Mergaert has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Miriam Shapiro-Shelef
Department of Medicine, University of Wisconsin-Madison, Madison, WI, United States
3 shared publications S. Janna Bashar
University of Wisconsin‐Madison
3 shared publicationsMichael F. Denny
University of Wisconsin‐Madison
2 shared publicationsAdrian B. McDermott
Vaccine Immunology Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, MD
1 shared publication- Ajay K. Sethi
Department of Population Health Sciences, University of Wisconsin, Madison, WI 53726, USA
1 shared publication - Alison Taylor
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA
1 shared publication
Latest Publications
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 1994
Abstract 1994: Defining tumor infiltrating myeloid microenvironment landscapes in HPV+ and HPV- head and neck cancers
Head and neck cancer (HNC) has a <20% response rate to immunotherapy, making it imperative to learn what causes high treatment resistance and how to overcome these challenges. One way to generate a holistic view of both human papillomavirus positive (HPV+) and negative (HPV-) HNC is to study the tumor immune microenvironment (TIME). Since HPV+ HNC often results in more favorable outcomes than HPV- HNC, assessing differences between these two disease states may provide critical mechanistic insight into what causes discrepancies in treatment response. This study uses publicly available and in-house collected single-cell transcriptome (scRNA-seq) data from preclinical murine models and human HNC to assess the differences between HPV+ and HPV- HNC TIME. Recent scRNA-Seq data showed extensive characterization of infiltrating T and B cells between HPV+ and HPV- HNC, but little is known about the myeloid compartment. As myeloid cells with both pro- and anti-tumoral functions make up a bulk of the HNC TIME, we sought to identify the differences in myeloid cells between HPV+ vs. HPV- HNC and their roles in response to immune checkpoint inhibitor (ICI) therapy. We identified higher myeloid heterogeneity than previously reported from both published and our generated scRNA-Seq. In human HNC patients, we identified four macrophage, seven monocyte, and five dendritic cell subsets. One macrophage subset expressed high levels of CXCL9 in both humans and our murine HNC model. Interestingly, recent studies identified CXCL9 as a biomarker for immunotherapy response. Observing conserved Cxcl9-expressing macrophages between murine and human HNC could help assess treatment response in cancer patients. We will assess the translational value of murine HPV+ and HPV- HNC models compared to their human counterparts. To this end, we are generating scRNA-Seq data from different HNC murine models: MOC1, MOC2, mEERL. The MOC2 and MOC1 cell lines recapitulate a responsive and non-responsive HPV- HNC tumor phenotype, respectively. The mEERL cell line recapitulates an HPV+ HNC phenotype. Our analysis shows high concordance between mouse models with immunological cold TIME (MOC2) and a proportion of human HNCs. We also identified changes in myeloid landscapes between immunological cold-to-hot TIME mice receiving ICI (anti-PD1 + anti-CTL4) therapies. We will present an in-depth comparative analysis to provide mechanistic insights into observed differences in the TIME between mice and humans. We will also present a novel bioinformatics analysis to interrogate how cell-cell signaling interactions between myeloid and T cell subsets influence their downstream gene regulatory network and tumor immune phenotypes. This analysis provides a reference for future studies in HNC immunology. Citation Format: Athena E. Golfinos, Wei Wang, Aisha Mergaert, Paul F. Lambert, Huy Q. Dinh. Defining tumor infiltrating myeloid microenvironment landscapes in HPV+ and HPV- head and neck cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1994.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 1994
Open AccessAbstract 1994: Defining tumor infiltrating myeloid microenvironment landscapes in HPV+ and HPV- head and neck cancers
Head and neck cancer (HNC) has a <20% response rate to immunotherapy, making it imperative to learn what causes high treatment resistance and how to overcome these challenges. One way to generate a holistic view of both human papillomavirus positive (HPV+) and negative (HPV-) HNC is to study the tumor immune microenvironment (TIME). Since HPV+ HNC often results in more favorable outcomes than HPV- HNC, assessing differences between these two disease states may provide critical mechanistic insight into what causes discrepancies in treatment response. This study uses publicly available and in-house collected single-cell transcriptome (scRNA-seq) data from preclinical murine models and human HNC to assess the differences between HPV+ and HPV- HNC TIME. Recent scRNA-Seq data showed extensive characterization of infiltrating T and B cells between HPV+ and HPV- HNC, but little is known about the myeloid compartment. As myeloid cells with both pro- and anti-tumoral functions make up a bulk of the HNC TIME, we sought to identify the differences in myeloid cells between HPV+ vs. HPV- HNC and their roles in response to immune checkpoint inhibitor (ICI) therapy. We identified higher myeloid heterogeneity than previously reported from both published and our generated scRNA-Seq. In human HNC patients, we identified four macrophage, seven monocyte, and five dendritic cell subsets. One macrophage subset expressed high levels of CXCL9 in both humans and our murine HNC model. Interestingly, recent studies identified CXCL9 as a biomarker for immunotherapy response. Observing conserved Cxcl9-expressing macrophages between murine and human HNC could help assess treatment response in cancer patients. We will assess the translational value of murine HPV+ and HPV- HNC models compared to their human counterparts. To this end, we are generating scRNA-Seq data from different HNC murine models: MOC1, MOC2, mEERL. The MOC2 and MOC1 cell lines recapitulate a responsive and non-responsive HPV- HNC tumor phenotype, respectively. The mEERL cell line recapitulates an HPV+ HNC phenotype. Our analysis shows high concordance between mouse models with immunological cold TIME (MOC2) and a proportion of human HNCs. We also identified changes in myeloid landscapes between immunological cold-to-hot TIME mice receiving ICI (anti-PD1 + anti-CTL4) therapies. We will present an in-depth comparative analysis to provide mechanistic insights into observed differences in the TIME between mice and humans. We will also present a novel bioinformatics analysis to interrogate how cell-cell signaling interactions between myeloid and T cell subsets influence their downstream gene regulatory network and tumor immune phenotypes. This analysis provides a reference for future studies in HNC immunology. Citation Format: Athena E. Golfinos, Wei Wang, Aisha Mergaert, Paul F. Lambert, Huy Q. Dinh. Defining tumor infiltrating myeloid microenvironment landscapes in HPV+ and HPV- head and neck cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1994.
- 10 April 2022
- Published by Wiley in Arthritis & Rheumatology
- Vol. 74 (6) , 984-991
Rheumatoid Factor and Anti–Modified Protein Antibody Reactivities Converge on IgG Epitopes
Objective: Rheumatoid arthritis (RA) patients often develop rheumatoid factors (RFs), antibodies that bind IgG Fc, and anti–modified protein antibodies (AMPAs), multireactive autoantibodies that commonly bind citrullinated, homocitrullinated, and acetylated antigens. Recently, antibodies that bind citrulline‐containing IgG epitopes were discovered in RA, suggesting that additional undiscovered IgG epitopes could exist and that IgG could be a shared antigen for RFs and AMPAs. This study was undertaken to reveal new IgG epitopes in rheumatic disease and to determine if multireactive AMPAs bind IgG.Methods: Using sera from patients with RA, systemic lupus erythematosus, Sjögren's disease (SjD), or spondyloarthropathy, IgG binding to native, citrulline‐containing, and homocitrulline‐containing linear epitopes of the IgG constant region was evaluated by peptide array, with highly bound epitopes further evaluated by enzyme‐linked immunosorbent assay (ELISA). Binding of monoclonal AMPAs to IgG‐derived peptides and IgG Fc was also evaluated by ELISA.Results: Seropositive RA sera showed high IgG binding to multiple citrulline‐ and homocitrulline‐containing IgG‐derived peptides, whereas anti‐SSA+ sera from SjD patients showed consistent binding to a single linear native epitope of IgG in the hinge region. Monoclonal AMPAs bound citrulline‐ and homocitrulline‐containing IgG peptides and modified IgG Fc.Conclusion: The repertoire of epitopes bound by AMPAs includes modified IgG epitopes, positioning IgG as a common antigen that connects the otherwise divergent reactivities of RFs and AMPAs.
- 10 April 2022
- Published by Wiley in Arthritis & Rheumatology
- Vol. 74 (6) , 984-991
Rheumatoid Factor and Anti–Modified Protein Antibody Reactivities Converge on IgG Epitopes
Objective: Rheumatoid arthritis (RA) patients often develop rheumatoid factors (RFs), antibodies that bind IgG Fc, and anti–modified protein antibodies (AMPAs), multireactive autoantibodies that commonly bind citrullinated, homocitrullinated, and acetylated antigens. Recently, antibodies that bind citrulline‐containing IgG epitopes were discovered in RA, suggesting that additional undiscovered IgG epitopes could exist and that IgG could be a shared antigen for RFs and AMPAs. This study was undertaken to reveal new IgG epitopes in rheumatic disease and to determine if multireactive AMPAs bind IgG.Methods: Using sera from patients with RA, systemic lupus erythematosus, Sjögren's disease (SjD), or spondyloarthropathy, IgG binding to native, citrulline‐containing, and homocitrulline‐containing linear epitopes of the IgG constant region was evaluated by peptide array, with highly bound epitopes further evaluated by enzyme‐linked immunosorbent assay (ELISA). Binding of monoclonal AMPAs to IgG‐derived peptides and IgG Fc was also evaluated by ELISA.Results: Seropositive RA sera showed high IgG binding to multiple citrulline‐ and homocitrulline‐containing IgG‐derived peptides, whereas anti‐SSA+ sera from SjD patients showed consistent binding to a single linear native epitope of IgG in the hinge region. Monoclonal AMPAs bound citrulline‐ and homocitrulline‐containing IgG peptides and modified IgG Fc.Conclusion: The repertoire of epitopes bound by AMPAs includes modified IgG epitopes, positioning IgG as a common antigen that connects the otherwise divergent reactivities of RFs and AMPAs.
- Open Access
- 17 January 2022
- Published by Wiley in Journal of Immunology Research
- Vol. 2022, 1-12
Peptidylarginine Deiminase 2 in Murine Antiviral and Autoimmune Antibody Responses
The peptidylarginine deiminases (PADs) and the citrullinated proteins that they generate have key roles in innate immunity and rheumatoid arthritis, an inflammatory arthritis with antibodies that target citrullinated proteins. However, the importance of PADs, particularly PAD2, in the adaptive immune response, both normal and pathogenic, is newly emerging. In this study, we evaluated a requirement for PAD2 in the antibody response in collagen-induced arthritis (CIA), a T and B cell-driven murine model of rheumatoid arthritis, and in the protective antibody response to murine influenza infection. Using PAD2-/- and PAD2+/+ mice on the DBA/1J background, we found that PAD2 is required for maximal anti-collagen antibody levels, but not collagen-specific plasma cell numbers, T cell activation or polarization, or arthritis severity in CIA. Also, we found that PAD2 is required not just for normal levels of persistent hemagglutination inhibiting antibodies but also for full protection from lethal influenza rechallenge. Together, these data provide evidence for a novel modest requirement for PAD2 in a normal antiviral antibody response and in an abnormal autoantibody response in inflammatory arthritis.
- 17 January 2022
- Published by Wiley in Journal of Immunology Research
- Vol. 2022, 1-12
Open AccessPeptidylarginine Deiminase 2 in Murine Antiviral and Autoimmune Antibody Responses
The peptidylarginine deiminases (PADs) and the citrullinated proteins that they generate have key roles in innate immunity and rheumatoid arthritis, an inflammatory arthritis with antibodies that target citrullinated proteins. However, the importance of PADs, particularly PAD2, in the adaptive immune response, both normal and pathogenic, is newly emerging. In this study, we evaluated a requirement for PAD2 in the antibody response in collagen-induced arthritis (CIA), a T and B cell-driven murine model of rheumatoid arthritis, and in the protective antibody response to murine influenza infection. Using PAD2-/- and PAD2+/+ mice on the DBA/1J background, we found that PAD2 is required for maximal anti-collagen antibody levels, but not collagen-specific plasma cell numbers, T cell activation or polarization, or arthritis severity in CIA. Also, we found that PAD2 is required not just for normal levels of persistent hemagglutination inhibiting antibodies but also for full protection from lethal influenza rechallenge. Together, these data provide evidence for a novel modest requirement for PAD2 in a normal antiviral antibody response and in an abnormal autoantibody response in inflammatory arthritis.
- Open Access
- 1 June 2021
- Published by Oxford University Press (OUP) in ImmunoHorizons
- Vol. 5 (6) , 466-476
Specific COVID-19 Symptoms Correlate with High Antibody Levels against SARS-CoV-2
Lasting immunity will be critical for overcoming COVID-19. However, the factors associated with the development of high titers of anti–SARS-CoV-2 Abs and how long those Abs persist remain incompletely defined. In particular, an understanding of the relationship between COVID-19 symptoms and anti–SARS-CoV-2 Abs is limited. To address these unknowns, we quantified serum anti–SARS- CoV-2 Abs in clinically diverse COVID-19 convalescent human subjects 5 wk (n = 113) and 3 mo (n = 79) after symptom resolution with three methods: a novel multiplex assay to quantify IgG against four SARS-CoV-2 Ags, a new SARS-CoV-2 receptor binding domain-angiotensin converting enzyme 2 inhibition assay, and a SARS-CoV-2 neutralizing assay. We then identified clinical and demographic factors, including never-before-assessed COVID-19 symptoms, that consistently correlate with high anti–SARS-CoV-2 Ab levels. We detected anti–SARS-CoV-2 Abs in 98% of COVID-19 convalescent subjects 5 wk after symptom resolution, and Ab levels did not decline at 3 mo. Greater disease severity, older age, male sex, higher body mass index, and higher Charlson Comorbidity Index score correlated with increased anti–SARS-CoV-2 Ab levels. Moreover, we report for the first time (to our knowledge) that COVID-19 symptoms, most consistently fever, body aches, and low appetite, correlate with higher anti–SARS-CoV-2 Ab levels. Our results provide robust and new insights into the development and persistence of anti–SARS-CoV-2 Abs.
- 1 June 2021
- Published by Oxford University Press (OUP) in ImmunoHorizons
- Vol. 5 (6) , 466-476
Open AccessSpecific COVID-19 Symptoms Correlate with High Antibody Levels against SARS-CoV-2
Lasting immunity will be critical for overcoming COVID-19. However, the factors associated with the development of high titers of anti–SARS-CoV-2 Abs and how long those Abs persist remain incompletely defined. In particular, an understanding of the relationship between COVID-19 symptoms and anti–SARS-CoV-2 Abs is limited. To address these unknowns, we quantified serum anti–SARS- CoV-2 Abs in clinically diverse COVID-19 convalescent human subjects 5 wk (n = 113) and 3 mo (n = 79) after symptom resolution with three methods: a novel multiplex assay to quantify IgG against four SARS-CoV-2 Ags, a new SARS-CoV-2 receptor binding domain-angiotensin converting enzyme 2 inhibition assay, and a SARS-CoV-2 neutralizing assay. We then identified clinical and demographic factors, including never-before-assessed COVID-19 symptoms, that consistently correlate with high anti–SARS-CoV-2 Ab levels. We detected anti–SARS-CoV-2 Abs in 98% of COVID-19 convalescent subjects 5 wk after symptom resolution, and Ab levels did not decline at 3 mo. Greater disease severity, older age, male sex, higher body mass index, and higher Charlson Comorbidity Index score correlated with increased anti–SARS-CoV-2 Ab levels. Moreover, we report for the first time (to our knowledge) that COVID-19 symptoms, most consistently fever, body aches, and low appetite, correlate with higher anti–SARS-CoV-2 Ab levels. Our results provide robust and new insights into the development and persistence of anti–SARS-CoV-2 Abs.